Co-amilozide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Co-amilozide
Combination of
Amiloride Potassium-sparing diuretic
Hydrochlorothiazide Thiazide diuretic
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Identifiers
PubChem CID
ChemSpider
  (verify)

Co-amilozide (BAN) is a non-proprietary combination of amiloride and hydrochlorothiazide. Co-amilozide is used in the treatment of hypertension and congestive heart failure with the tendency of the thiazide to cause low potassium levels (hypokalaemia) offset by the potassium-sparing effects of amiloride.

Formulation[edit]

Two strengths of co-amilozide are currently available in the UK:[1]

  • 2.5 mg amiloride and 25 mg hydrochlorothiazide, BAN of Co-amilozide 2.5/25 (brand name Moduret 25)
  • 5 mg amiloride and 50 mg hydrochlorothiazide, BAN of Co-amilozide 5/50 (brand name Moduretic)

In North America:

  • Moduretic (U.S., Canada)
    • Moduretic 5-50 (U.S., Canada)
  • Novamilor (Canada)

Side effects[edit]

The most common side effect is headache (about 8% of people taking it) and nausea, loss of appetite, weakness, rash and dizziness (each about 3%).[2]

Common side effects (1/10 - 1/100) include:[2]

  • General: Weakness, fatigue, loss of appetite. Headache, dizziness.
  • Circulatory system: Arrhythmia.
  • Gastrointestinal: Nausea, diarrhea, abdominal pain.
  • Skin: Exanthema, itching.
  • Respiratory system: dyspnoea, cough.
  • Metabolic.: Hyperglycemia in diabetic patients, hyperuricemia.
  • Musculoskeletal.: Pain in the limbs.

References[edit]

  1. ^ British National Formulary 54 September 2007
  2. ^ a b the Swedish official drug catalog > Normorix Retrieved on Mars 30, 2010